Phase Ⅱ Clinical Trial of ssCART-19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Latest Information Update: 25 Apr 2024
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
- 18 Apr 2024 New trial record